Measles cases hit a year high. Here's what payers need to know about outbreak costs, MMR coverage, and plans to split the vaccine
|Articles|May 1, 2000
Supplements and Featured Publications
- Emerging Drug-Resistant Pathogens in Respiratory Tract Infections: Treatment Options
- Volume 6
- Issue 8 Suppl
The Importance of Appropriate Treatment of Chronic Bronchitis
Author(s)Antonio Anzueto, MD
Advertisement
Articles in this issue
over 26 years ago
Participating Facultyover 26 years ago
Introductionover 26 years ago
Emerging Resistance Problems Among Respiratory Tract Pathogensover 26 years ago
Selected Abstractsover 26 years ago
BibliographyAdvertisement
Related to this article
As peptides go mainstream, the FDA's shifting rules and a fractured state patchwork leave patients navigating a largely unregulated gray market.
Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.
A large propensity-matched study linked outpatient melatonin use to a small reduction in REM sleep in children evaluated for polysomnography.
Prior authorization and compounded drugs remain top obesity care access barriers, says NYU Langone's Holly Lofton, MD.
Panelists say IRA, Most Favored Nation rules and fragmented data are freezing value-based deals for durable one-time therapies.
Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.
FDA approved belzutifan plus lenvatinib for advanced ccRCC after PD-1/PD-L1 therapy, expanding treatment options for those with disease progression.
Advertisement
Advertisement
Trending on AJMC
1
Surrogate End Points, Drug Costs Complicate Oncology Formularies
2
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
3
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
4
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
5